Literature DB >> 7865177

Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice.

M L Carlsson1, G Engberg, A Carlsson.   

Abstract

We have previously observed that an N-methyl-D-aspartate (NMDA) antagonist in combination with the alpha 2-adrenoceptor agonist clonidine produces a marked locomotor stimulation in monoamine-depleted mice. In this paper we report on how the partial glycine agonists D-cycloserine (high intrinsic activity) and (+)-HA-966 [(+)-3-amino-1-hydroxypyrrolid-2-one; low intrinsic activity] affect this response; the interaction with both an uncompetitive and a competitive NMDA antagonist was investigated. (+)-HA-966 was found to counteract the locomotor stimulation produced by clonidine combined with either an uncompetitive (MK-801 = dizocilpine) or a competitive [D-CPPene = 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid] NMDA antagonist. D-cycloserine potentiated the locomotor stimulation produced by either NMDA antagonist combined with clonidine, although statistical significance was achieved only in the case of MK-801. If the present hyperactivity model has any relevance for psychosis the prediction based on the present results would be that d-cycloserine, contrary to current hopes, might not be so effective in schizophrenia, whereas (+)-HA-966 might be an interesting candidate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865177     DOI: 10.1007/bf01271568

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  29 in total

Review 1.  Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.

Authors:  D C Javitt
Journal:  Hillside J Clin Psychiatry       Date:  1987

Review 2.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

Authors:  M Carlsson; A Carlsson
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

3.  An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy.

Authors:  R B Rosse; B L Schwartz; M P Leighton; R E Davis; S I Deutsch
Journal:  Clin Neuropharmacol       Date:  1990-08       Impact factor: 1.592

Review 4.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.

Authors:  S I Deutsch; J Mastropaolo; B L Schwartz; R B Rosse; J M Morihisa
Journal:  Clin Neuropharmacol       Date:  1989-02       Impact factor: 1.592

5.  In vivo demonstration of the enhancement of MK-801 by L-glutamate.

Authors:  R B Raffa; M E Ortegón; D M Robisch; G E Martin
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

6.  d-Cycloserine therapy of psychosis by symptom provocation.

Authors:  J Simeon; M Fink; T M Itil; D Ponce
Journal:  Compr Psychiatry       Date:  1970-01       Impact factor: 3.735

7.  Multiple sites for the regulation of the N-methyl-D-aspartate receptor.

Authors:  I J Reynolds; R J Miller
Journal:  Mol Pharmacol       Date:  1988-06       Impact factor: 4.436

8.  Glutamate and glycine co-activate while polyamines merely modulate the NMDA receptor complex.

Authors:  J Lehmann; F Colpaert; H Canton
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1991       Impact factor: 5.067

9.  The glycine site of the N-methyl-D-aspartate receptor channel: differences between the binding of HA-966 and of 7-chlorokynurenic acid.

Authors:  Y Kloog; H Lamdani-Itkin; M Sokolovsky
Journal:  J Neurochem       Date:  1990-05       Impact factor: 5.372

10.  Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent gamma-butyrolactone-like sedative.

Authors:  L Singh; A E Donald; A C Foster; P H Hutson; L L Iversen; S D Iversen; J A Kemp; P D Leeson; G R Marshall; R J Oles
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

View more
  3 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  The glycine antagonist (+)-HA-966 injected into the nucleus accumbens stimulates locomotion in mice. (Rapid communication).

Authors:  M Nilsson; M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia.

Authors:  Andrea Balla; Samantha Schneider; Henry Sershen; Daniel C Javitt
Journal:  Eur Neuropsychopharmacol       Date:  2012-05-05       Impact factor: 4.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.